HOME >> MEDICINE >> NEWS
UK approval procedures will drive research overseas

Approval procedures for UK research will "accelerate the migration of clinical studies to other parts of the world," warn researchers in a letter to this week's BMJ.

They describe the problems experienced by a research team that wanted to assess the impact of modernising endoscopy services in 20 NHS trusts in England.

Substantial variation occurred in the application procedures. Some trusts gave approval authority to one person while others relied on research and development committees, which typically sat monthly, resulting in delays. Documentation was "lost" in two trusts.

Obtaining research governance approval for all 20 trusts required 103 days. With the addition of the 47 days taken to obtain ethical approval, this resulted in a total delay of 150 days.

Research studies requiring multiple NHS sites should build in substantial lag times before research processes can be initiated, say the authors.

"We anticipate that failure to address this new obstacle to health service research will block evaluation work and accelerate the migration of clinical studies to other parts of the world," they conclude.


'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
7-Apr-2005


Page: 1

Related medicine news :

1. Sutent achieves first line EAU approval for kidney cancer
2. Breast cancer drug receives FDA approval
3. March of Dimes: Drug to prevent preterm birth needs prompt FDA approval
4. REVLIMID(R) granted approval by FDA for treatment of multiple myeloma
5. Worlds first approval of new HIV drug TMC114 provides potent new treatment option with FUZEON
6. Aussie of the Year wins approval for cervical cancer vaccine
7. UC Berkeley team helps win approval for life-saving drug for African women
8. Cincinnati Childrens applauds EU approval of rotavirus vaccine
9. TPV EU approval provides new HIV active drug to be combined with FUZEON
10. ASH Self-Assessment Program receives approval for maintenance of certification credit
11. GlaxoSmithKline announces FDA approval of Fluarix

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: approval procedures will drive research overseas

(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... disease Amyotrophic lateral sclerosis (ALS), also known as Lou ... can be classified into four distinct stages, report pathologists ... of Pennsylvania in the Annals of Neurology . ... tissues shows, for the first time, how the fatal ... the central nervous system to other regions of brain ...
(Date:6/19/2013)... derived from a naturally occurring compound (apocynin), has ... with Parkinson,s Disease symptoms by preventing deficits in ... the May 28, 2013 edition of ... postdoctoral fellow at the Medical College of Wisconsin ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
(Date:6/19/2013)... , June 19, 2013   Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  ... company focused on the development and commercialization of novel ... announced the pricing of an underwritten public offering of ... offering price of $33.01 per share.  In addition, Intercept ... up to an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: